These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 26766027)

  • 21. Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study.
    Koppara T; Tada T; Xhepa E; Kufner S; Byrne RA; Ibrahim T; Laugwitz KL; Kastrati A; Joner M
    Int J Cardiol; 2018 May; 258():42-49. PubMed ID: 29544956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
    Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent.
    Toledano Delgado FJ; Alvarez-Ossorio MP; de Lezo Cruz-Conde JS; Bellido FM; Romero Moreno MÁ; Fernández-Aceytuno AM; de Lezo Herrerosde Tejada JS; Pineda SO; Saint-Gerons JM; Pavlovic D
    Catheter Cardiovasc Interv; 2014 Nov; 84(5):720-6. PubMed ID: 24174291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial.
    Adriaenssens T; Dens J; Ughi G; Bennett J; Dubois C; Sinnaeve P; Wiyono S; Coosemans M; Belmans A; D'hooge J; Vrolix M; Desmet W
    EuroIntervention; 2014 Aug; 10(4):439-48. PubMed ID: 25138182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy: A Randomized Trial.
    Lee SY; Kim JS; Yoon HJ; Hur SH; Lee SG; Kim JW; Hong YJ; Kim KS; Choi SY; Shin DH; Nam CM; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    JACC Cardiovasc Imaging; 2018 Dec; 11(12):1810-1819. PubMed ID: 29454763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Six-month follow-up evaluation for everolimus-eluting stents by intracoronary optical coherence tomography: comparison with paclitaxel-eluting stents.
    Takano M; Murakami D; Yamamoto M; Kurihara O; Murai K; Inami T; Kimata N; Ohba T; Seino Y; Mizuno K
    Int J Cardiol; 2013 Jun; 166(1):181-6. PubMed ID: 22075410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of acute stent malapposition between platinum-chromium versus cobalt-chromium everolimus-eluting stents.
    Kim BK; Shin DH; Kim JS; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2015 Feb; 31(2):269-77. PubMed ID: 25345751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optical coherence tomography findings: insights from the "randomised multicentre trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions" (PRISON IV) trial.
    Teeuwen K; Spoormans EM; Bennett J; Dubois C; Desmet W; Ughi GJ; Belmans A; Kelder JC; Tijssen JGP; Agostoni P; Suttorp MJ; Adriaenssens T
    EuroIntervention; 2017 Aug; 13(5):e522-e530. PubMed ID: 28512069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
    Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
    Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of different stent alloys on human vascular response to everolimus-eluting stent: an optical coherence tomography study: the OCTEVEREST.
    Guagliumi G; Capodanno D; Ikejima H; Bezerra HG; Sirbu V; Musumeci G; Fiocca L; Lortkipanidze N; Vassileva A; Tahara S; Valsecchi O; Costa MA
    Catheter Cardiovasc Interv; 2013 Feb; 81(3):510-8. PubMed ID: 22431208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
    Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schömig A; Kastrati A
    Cardiovasc Revasc Med; 2013; 14(2):84-9. PubMed ID: 23352095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
    Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
    Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial.
    Rai H; Alfonso F; Maeng M; Bradaric C; Wiebe J; Cuesta J; Christiansen EH; Cassese S; Hoppmann P; Colleran R; Harzer F; Bresha J; Nano N; Schneider S; Laugwitz KL; Joner M; Kastrati A; Byrne RA
    Int J Cardiovasc Imaging; 2021 Oct; 37(10):2815-2826. PubMed ID: 34420177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
    Gomez-Lara J; Brugaletta S; Diletti R; Garg S; Onuma Y; Gogas BD; van Geuns RJ; Dorange C; Veldhof S; Rapoza R; Whitbourn R; Windecker S; Garcia-Garcia HM; Regar E; Serruys PW
    Eur Heart J; 2011 Feb; 32(3):294-304. PubMed ID: 21123276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optical coherence tomography analysis of strut coverage in biolimus- and sirolimus-eluting stents: 3-month and 12-month serial follow-up.
    Kim BK; Hong MK; Shin DH; Kim JS; Ko YG; Choi D; Jang Y
    Int J Cardiol; 2013 Oct; 168(5):4617-23. PubMed ID: 23932862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
    Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26446596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials.
    Vlachojannis GJ; Puricel S; Natsuaki M; Morimoto T; Smits PC; Kimura T
    EuroIntervention; 2017 Mar; 12(16):1970-1977. PubMed ID: 27802927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.